Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
1-month rifapentine plus isoniazid for tuberculosis prevention in people with diabetes
ISRCTN37955921Phase 4Recruiting
- Sponsor
- University of Cape Town
- Start
- Jul 2025
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, open-label trial of rifapentine and isoniazid in latent tuberculosis infection (LTBI) and Tuberculosis (TB) (2 arms), sponsored by University of Cape Town. Started Jul 2025; status: recruiting.
02
Drugs
rifapentineisoniazid
03
Conditions
latent tuberculosis infection (LTBI)Tuberculosis (TB)
Beyond the preview
Go deeper on ISRCTN37955921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN37955921.